Cargando…
Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors
Proliferative and invasive breast tumors evolve heterogeneously in individual patients, posing significant challenges in identifying new druggable targets for precision, effective therapy. Here we present a functional multi-omics method, interaction-Correlated Multi-omic Aberration Patterning (iC-MA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660457/ https://www.ncbi.nlm.nih.gov/pubmed/31336272 http://dx.doi.org/10.1016/j.isci.2019.07.001 |
_version_ | 1783439301775720448 |
---|---|
author | Wrobel, John A. Xie, Ling Wang, Li Liu, Cui Rashid, Naim Gallagher, Kristalyn K. Xiong, Yan Konze, Kyle D. Jin, Jian Gatza, Michael L. Chen, Xian |
author_facet | Wrobel, John A. Xie, Ling Wang, Li Liu, Cui Rashid, Naim Gallagher, Kristalyn K. Xiong, Yan Konze, Kyle D. Jin, Jian Gatza, Michael L. Chen, Xian |
author_sort | Wrobel, John A. |
collection | PubMed |
description | Proliferative and invasive breast tumors evolve heterogeneously in individual patients, posing significant challenges in identifying new druggable targets for precision, effective therapy. Here we present a functional multi-omics method, interaction-Correlated Multi-omic Aberration Patterning (iC-MAP), which dissects intra-tumor heterogeneity and identifies in situ the oncogenic consequences of multi-omics aberrations that drive proliferative and invasive tumors. First, we perform chromatin activity-based chemoproteomics (ChaC) experiments on breast cancer (BC) patient tissues to identify genetic/transcriptomic alterations that manifest as oncogenically active proteins. ChaC employs a biotinylated small molecule probe that specifically binds to the oncogenically active histone methyltransferase G9a, enabling sorting/enrichment of a G9a-interacting protein complex that represents the predominant BC subtype in a tissue. Second, using patient transcriptomic/genomic data, we retrospectively identified some G9a interactor-encoding genes that showed individualized iC-MAP. Our iC-MAP findings represent both new diagnostic/prognostic markers to identify patient subsets with incurable metastatic disease and targets to create individualized therapeutic strategies. |
format | Online Article Text |
id | pubmed-6660457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-66604572019-08-05 Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors Wrobel, John A. Xie, Ling Wang, Li Liu, Cui Rashid, Naim Gallagher, Kristalyn K. Xiong, Yan Konze, Kyle D. Jin, Jian Gatza, Michael L. Chen, Xian iScience Article Proliferative and invasive breast tumors evolve heterogeneously in individual patients, posing significant challenges in identifying new druggable targets for precision, effective therapy. Here we present a functional multi-omics method, interaction-Correlated Multi-omic Aberration Patterning (iC-MAP), which dissects intra-tumor heterogeneity and identifies in situ the oncogenic consequences of multi-omics aberrations that drive proliferative and invasive tumors. First, we perform chromatin activity-based chemoproteomics (ChaC) experiments on breast cancer (BC) patient tissues to identify genetic/transcriptomic alterations that manifest as oncogenically active proteins. ChaC employs a biotinylated small molecule probe that specifically binds to the oncogenically active histone methyltransferase G9a, enabling sorting/enrichment of a G9a-interacting protein complex that represents the predominant BC subtype in a tissue. Second, using patient transcriptomic/genomic data, we retrospectively identified some G9a interactor-encoding genes that showed individualized iC-MAP. Our iC-MAP findings represent both new diagnostic/prognostic markers to identify patient subsets with incurable metastatic disease and targets to create individualized therapeutic strategies. Elsevier 2019-07-04 /pmc/articles/PMC6660457/ /pubmed/31336272 http://dx.doi.org/10.1016/j.isci.2019.07.001 Text en © 2019. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Wrobel, John A. Xie, Ling Wang, Li Liu, Cui Rashid, Naim Gallagher, Kristalyn K. Xiong, Yan Konze, Kyle D. Jin, Jian Gatza, Michael L. Chen, Xian Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors |
title | Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors |
title_full | Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors |
title_fullStr | Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors |
title_full_unstemmed | Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors |
title_short | Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors |
title_sort | multi-omic dissection of oncogenically active epiproteomes identifies drivers of proliferative and invasive breast tumors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660457/ https://www.ncbi.nlm.nih.gov/pubmed/31336272 http://dx.doi.org/10.1016/j.isci.2019.07.001 |
work_keys_str_mv | AT wrobeljohna multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT xieling multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT wangli multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT liucui multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT rashidnaim multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT gallagherkristalynk multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT xiongyan multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT konzekyled multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT jinjian multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT gatzamichaell multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors AT chenxian multiomicdissectionofoncogenicallyactiveepiproteomesidentifiesdriversofproliferativeandinvasivebreasttumors |